{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.4","value":"913.9"},{"groupId":"OG001","spread":"20.6","value":"1002.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Maximum observed concentration of Romidepsin","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Each patient enrolled in the PK portion underwent one PK sampling period on Day 1 of Cycle 1, following the administration of Bortezomib and 1-hour IV infusion of romidepsin 8mg/m\\^2.","id":"OG000","title":"Romidepsin 8 mg/m^2 + Bortezomib"},{"description":"Each patient enrolled in the PK portion underwent one PK sampling period on Day 1 of Cycle 1, following the administration of Bortezomib and 1-hour IV infusion of romidepsin 10mg/m\\^2.","id":"OG001","title":"Romidepsin 10 mg/m^2 + Bortezomib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"A subset of participants from the lead investigator's site had PK samples taken.","reportingStatus":"POSTED","timeFrame":"Day 1 (cycle 1): 1 hour prior to romidepsin administration, 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after initiation of romidepsin infusion","title":"Maximum Observed Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}